GlobeNewswire Inc | Sep 10, 2020 08:39AM EDT

September 10, 2020

JERSEY CITY, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Marco Taglietti, Chief Executive Officer, will participate in a fireside chat at H.C. Wainwrights 22nd Annual Global Investment Healthcare Conference taking place September 14-16, 2020. Dr. Taglietti will also partake in a panel discussion at Maxims antifungal webinar taking place September 17, 2020.

Presentation details:

H.C. Wainwright 22^nd Annual Global Investment ConferencePresentation Tuesday, September 15, 2020Date:Presentation 2:30 p.m. ETTime:Webcast: https://wsw.com/webcast/hcw7/register.aspx?conf=hcw7&page=scyx&url = https://wsw.com/webcast/hcw7/scyx Maxim?s Antifungal WebinarWebinar A Too Quiet Pandemic ? Fungal DiseaseTopic:Date: Thursday, September 17, 2020Time: 11:00 a.m. ETRegister to attend via link

A webcast of the HCW presentation and a recording of the Maxim webinar will be available for 30 days on the SCYNEXIS website at: https://www.scynexis.com/news-media/events

AboutSCYNEXIS

SCYNEXIS, Inc.(NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. TheSCYNEXISteamhas extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate,ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused byCandidaandAspergillusspecies. For more information, visitwww.scynexis.com.

CONTACTInvestor RelationsIrina KofflerLifeSci AdvisorsTel: (646) 970-4681ikoffler@lifesciadvisors.com

Media RelationsGloria GasaaturaLifeSci CommunicationsTel: (646) 970-4688ggasaatura@lifescicomms.com